Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 39Other hematologic neoplasm 30Plasma cell 15CNS 10Sarcoma 7Genitourinary 7Breast 6Dermatologic 5Gynecologic 4Myeloid 3Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Sarcoma, Synovial 1Melanoma 1Advanced Fallopian Tube Carcinoma 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Leukapheresis × Gynecologic × Clear all
NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic

Phase 1 Recruiting
12 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT03318900 2024-11-07

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
5 enrolled 8 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡